Lanfan medical completed the acquisition of NVT AG, a Swiss transcatheter aortic valve replacement company

On June 10, blue sail Medical Co., Ltd("blue sail medical", securities code: 002382) announced that bluesail new valve technology HK Limited, a wholly-owned subsidiary of the company and Hong Kong, had signed the "confirmation of cutting" with NVT AG, a Swiss transcatheter aortic valve replacement (TAVR) company, Bluesail new valve technology HK Limited has become a shareholder holding 100% of NVT Ag directly< br / > the parties confirm that June 8, 2020 is the delivery date of this transaction, and lanfan medical has paid all transaction costs of EUR 139556651.39 and CHF 851016.53 to the seller's shareholders of NVT Ag in one time in accordance with the equity transfer agreement< br / > it is reported that in September 2019, blue sail medical signed equity purchase agreements with several sellers, with NVT Ag as the targetThe main product of NVT AG is allegratm, an implantable device of TAVR, which is mainly used for the treatment of aortic valve related diseasesAfter the acquisition, lanfan medical quickly acquired NVT's mature TAVR products and technologies, which will realize the leapfrog development of TAVR business from Europe to China and the global market.